Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas have?
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas has 40 citations in the OpenAlex counts ScholarIQ stores.
When was Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas published?
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas has 2015 year in the ScholarIQ index.
What is the open-access status of Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas?
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas has gold oa status in the ScholarIQ index.
What is the DOI of Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas?
The DOI for Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas is on the source record.
What is the PMID of Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas?
The PMID for Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas is on the source record.
What is the OpenAlex record for Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas?
The OpenAlex for Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas is on the source record.